

Indivior Publications 2013

Manuscripts

Early-Stage Discovery and Development

1. Heidbreder C. Rationale in support of the use of selective dopamine D3 receptor antagonists for the pharmacotherapeutic management of drug addiction. *Naunyn Schmiedebergs Arch Pharmacol.* 2013;386:167-176. <http://dx.doi.org/10.1007/s00210-012-0803-6>.
2. Micheli F, Heidbreder C. Selective dopamine D3 receptor antagonists 2007-2012: A patent review. *Expert Opin Ther Pat.* 2013;23(3):363-381. <http://dx.doi.org/10.1517/13543776.2013.757593>
3. Rice OV, Heidbreder CA, Gardner EL, Schonhar C, Ashby CR Jr. The selective D3 receptor antagonist SB-277011A attenuates morphine-triggered reactivation of expression of cocaine-induced conditioned place preference. *Synapse.* 2013;67(8):469-475. <http://dx.doi.org/10.1002/syn.21653>

Treatment of Schizophrenia

1. Gomeni R., Heidbreder C, Fudala PJ, Nasser AF. A model-based approach to characterize the population pharmacokinetics and the relationship between the pharmacokinetic and safety profiles of RBP-7000, a new, long-acting, sustained-released formulation of risperidone. *Clin. Pharmacol.* 2013;53(10):1010-1019. <http://dx.doi.org/10.1002/jcph.141>

Abstracts

Treatment of Schizophrenia

1. Gomeni R, Heidbreder C, Fudala PJ, Nasser A. A model-based approach to characterize the relationship between the long-lasting pharmacokinetic (PK) time-course and the safety profile of RBP-7000, a new sustained released formulation of risperidone. *Proceedings of the American Society for Clinical Pharmacology & Therapeutics (ASCPT).* Indianapolis, IN; March 5-9, 2013.
2. Gomeni R, Heidbreder C, Fudala PJ, Nasser A. A model-based approach to characterize the long-lasting pharmacokinetic (PK) time-course of RBP-7000, a new sustained released formulation of risperidone. *Proceedings of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).* Indianapolis, IN; March 5-9, 2013.